Cardiovascular Systems Inc.
Cardiovascular Systems wins CE Mark for Stealth 360 peripheral artery device
FDA grants Philips clearance for 3D TAVI software | Regulatory news for the week of August 25, 2014
Cardiovascular Systems recalls some Diamondback devices on embolism risk
Cardiovascular Systems launches COAST heart disease study
Boston Scientific’s peripherals buy bad news for Cardiovascular Systems? | Medtech Wall Street news for the week of May 19, 2014
MDT owes $15.4 million to bone cement maker Pabban Development | Medtech legal news for the week of May 19, 2014
Is Boston Scientific’s peripherals buy bad news for Cardiovascular Systems?
Boston Scientific’s (NYSE:BSX) $415 million acquisition of Bayer AG’s interventional unit is a strong move for the company, but it may bode ill for other peripheral players.
North Carolina DA probes Cardiovascular Systems
Cardiovascular Systems (NSDQ:CSII) late last week became the latest medical device company to reveal a federal probe into possible marketing or False Claims Act violations.
Teleflex announces plans to cut costs and streamline manufacturing | Medtech Wall Street news for the week of May 5, 2014
Cardiovascular Systems jumps as sales increase 32%
Cardiovascular Systems’ (NSDQ:CSII) revenues soared in its 3rd quarter, driven primarily by the popularity of the company’s Stealth 360 device, a peripheral artery disease treatment system.